Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mineralys Therapeutics, Inc. (Nasdaq: MLYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor, through clinical development. As a clinical-stage biopharmaceutical company focused on hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-driven diseases, Mineralys uses SEC filings to report financial results, capital-raising activities and other material events.
Current and prospective investors can review Form 8-K filings where Mineralys reports quarterly financial results and corporate updates, as well as transactions such as underwritten public offerings of common stock and changes to at-the-market equity programs. These documents often reference the company’s clinical progress with lorundrostat, including pivotal trials like Launch-HTN and Advance-HTN, Phase 2 programs such as Explore-CKD and Explore-OSA, and steps toward a potential New Drug Application (NDA) with the U.S. Food and Drug Administration.
Over time, the filings set is expected to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that elaborate on risk factors, liquidity, research and development spending, and the company’s dependence on the success of lorundrostat and key licensing arrangements. Investors may also monitor registration statements and prospectus supplements related to equity offerings, as reflected in referenced Form S-3 filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, such as trial-related disclosures, financing terms and forward-looking statements. Real-time updates from EDGAR, combined with tools to track items like material events and offering details, help users quickly understand how Mineralys Therapeutics’ regulatory and financial reporting aligns with its clinical and regulatory strategy for lorundrostat.
Mineralys Therapeutics, Inc. filed an 8‑K stating it issued a press release announcing financial results for the quarter ended September 30, 2025 and provided a corporate update. The press release is furnished as Exhibit 99.1.
Consistent with Item 2.02 treatment and General Instruction B.2, the information, including Exhibit 99.1, is furnished and not deemed filed or subject to Section 18 liabilities, and is not incorporated by reference except as specifically set forth.
Mineralys Therapeutics (MLYS) reported insider activity: its CFO and Secretary sold common stock in two open‑market transactions on 10/13/2025 under a Rule 10b5-1 trading plan adopted on November 14, 2023.
The sales covered 7,366 shares at a weighted‑average price of $41.9021 and 3,392 shares at a weighted‑average price of $42.2561. Following these transactions, the reporting person beneficially owned 116,865 shares. The filing notes that 5,311 shares were previously transferred to an ex‑spouse pursuant to a domestic relations order.
Mineralys Therapeutics (MLYS) disclosed insider sales by its Chief Executive Officer and director on 10/13/2025. The CEO sold 13,548 shares at a weighted-average price of $42.6295 (range $41.9800–$42.9800) and 1,552 shares at a weighted-average price of $43.0299 (range $42.9822–$43.2030) pursuant to a Rule 10b5-1 trading plan adopted on January 30, 2024. Following these transactions, the reporting person directly beneficially owned 831,305 shares.
Mineralys Therapeutics (MLYS) insider activity: The company’s Chief Medical Officer sold 10,369 shares of common stock on 10/15/2025 in an open-market transaction coded “S.” The sale was executed under a Rule 10b5-1 trading plan adopted on October 25, 2024.
The weighted-average price was $43.0111 per share, with individual trades ranging from $42.8000 to $43.1950. Following the transaction, the officer directly beneficially owns 71,155 shares.
Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), reported two open-market sales of company common stock on 09/15/2025 under a Rule 10b5-1 trading plan adopted on October 25, 2024. He sold a total of 11,367 shares in multiple transactions: 9,302 shares at a weighted-average price of $35.9004 and 2,065 shares at a weighted-average price of $36.4748. The filings show the sales occurred at prices within ranges of $35.4000–$36.3955 and $36.4026–$36.7005 respectively, and the reporting person is left with 83,589 and then 81,524 shares beneficially owned following each reported transaction. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Mineralys Therapeutics, Inc. (MLYS) Form 144 shows a proposed sale of 11,367 shares of common stock via Merrill Lynch with an aggregate market value of $409,266.28, to be sold approximately on 09/15/2025 on NASDAQ. The filer reports acquiring those shares by exercising employee stock options on 09/11/2024 (5,018 shares) and 09/12/2024 (6,349 shares), with cash payment on the acquisition dates. The filing lists 66,295,184 shares outstanding. The document also discloses two recent sales by the same person: 11,365 shares sold on 08/13/2025 for $146,987.47 and 11,366 shares sold on 07/14/2025 for $165,878.90. The broker named is Merrill Lynch, 225 Liberty St, New York.
Srinivas Akkaraju, a director of Mineralys Therapeutics (MLYS), reported an indirect purchase of 588,235 shares on 09/04/2025 at a reported price of $25.50 per share. The Form 4 shows those shares are held through Samsara Opportunity Fund, L.P., and the filing also reports beneficial ownership of 5,674,916 shares held indirectly through Samsara BioCapital, L.P. The filing includes standard disclaimers that the reporting person disclaims beneficial ownership except to the extent of pecuniary interest and explains the GP/LP relationships that give the reporting person voting and investment power over the funds' holdings.
Amendment No. 3 to a Schedule 13D reports that Samsara-affiliated entities and Dr. Srinivas Akkaraju collectively beneficially own 6,346,194 shares of Mineralys Therapeutics, Inc. common stock, representing 8.2% of the class. The filing discloses that on September 4, 2025, Samsara Opportunity Fund, L.P. purchased 588,235 shares at $25.50 per share in the issuer's public offering for an aggregate price of $14,999,993, funded by short-term borrowing from Samsara BioCapital, L.P. Ownership breakouts include 5,674,916 shares held by Samsara BioCapital, L.P. (7.3%) and 588,235 held by Samsara Opportunity Fund, L.P. (0.8%), with Dr. Akkaraju holding vested and near-vesting options that are included in his 8.2% figure. A 60-day lock-up from September 2, 2025 applies to directors and officers, including Dr. Akkaraju.
RA Capital and related persons report ownership of 7,796,433 shares of Mineralys Therapeutics (MLYS), representing 9.9% of the company on a stated basis. The filing amends prior Schedule 13D disclosures to reflect that on September 4, 2025 the RA Capital Healthcare Fund, L.P. purchased 1,176,470 shares in the issuer's September 2025 public offering at $25.50 per share for an aggregate $29,999,985 funded from the Fund's working capital. The reporting persons disclose 5,456,521 shares held directly by the Fund, 1,867,229 shares held by RA Capital Nexus Fund III, vested and soon-to-vest employee options, and Pre-Funded Warrants subject to a "Beneficial Ownership Blocker" that prevents exercise above 9.99% ownership. RA Capital serves as investment adviser and has sole voting and dispositive power for the Fund and Nexus Fund III, though the Fund and Nexus Fund III disclaim beneficial ownership for Section 13(d) purposes due to delegation of those powers.
RA Capital entities reported an acquisition of Mineralys Therapeutics (MLYS) common stock on 09/04/2025. The filing shows a purchase of 1,176,470 shares at $25.50 per share. After the transaction, the reporting persons disclosed 5,456,521 shares beneficially owned (indirect) and an additional line showing 1,867,229 shares beneficially owned (indirect), with holdings held directly by RA Capital Healthcare Fund, L.P. and Nexus Fund III, L.P. The filing identifies RA Capital Management, L.P. as adviser and names Dr. Peter Kolchinsky and Rajeev Shah among reporting individuals; a partner of the adviser, Dr. Derek DiRocco, serves on the issuer's board. The form is signed by the reporting persons on 09/08/2025.